1 Beaten-Down Stock to Buy and Hold for 10 Years
Viking Therapeutics (NASDAQ: VKTX) was one of the hottest biotech stocks of 2024; its shares soared last year following excellent clinical progress. However, things have been very different in 2025, at least so far: Its stock is down by 35% year to date due to a combination of factors.Should you steer clear of Viking Therapeutics? My view is that despite its struggles this year, there's still significant upside. Let's find out why it could be a top stock to hold for the long term.The biotech industry can be volatile, especially for small- or mid-cap drugmakers that don't have a single product on the market, a description that fits Viking Therapeutics. The company's shares soared last year on promising clinical progress for its leading candidate, VK2735, an investigational GLP-1 weight loss therapy. Not much has gone wrong since then, but many longtime shareholders likely took the opportunity to cash in on their gains after the significant jump last year.Continue reading
Viking Therapeutics (NASDAQ: VKTX) was one of the hottest biotech stocks of 2024; its shares soared last year following excellent clinical progress. However, things have been very different in 2025, at least so far: Its stock is down by 35% year to date due to a combination of factors.
Should you steer clear of Viking Therapeutics? My view is that despite its struggles this year, there's still significant upside. Let's find out why it could be a top stock to hold for the long term.
The biotech industry can be volatile, especially for small- or mid-cap drugmakers that don't have a single product on the market, a description that fits Viking Therapeutics. The company's shares soared last year on promising clinical progress for its leading candidate, VK2735, an investigational GLP-1 weight loss therapy. Not much has gone wrong since then, but many longtime shareholders likely took the opportunity to cash in on their gains after the significant jump last year.
